APRI - Apricus Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.39
+0.02 (+5.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.37
Open0.37
Bid0.00 x 800
Ask0.00 x 900
Day's Range0.36 - 0.39
52 Week Range0.25 - 3.34
Volume196,315
Avg. Volume810,073
Market Cap9.107M
Beta0.83
PE Ratio (TTM)N/A
EPS (TTM)-0.72
Earnings DateMay 9, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.25
Trade prices are not sourced from all markets
  • ACCESSWIRE16 days ago

    Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks

    On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • What Does Apricus Biosciences Inc’s (NASDAQ:APRI) Share Price Indicate?
    Simply Wall St.last month

    What Does Apricus Biosciences Inc’s (NASDAQ:APRI) Share Price Indicate?

    Apricus Biosciences Inc (NASDAQ:APRI), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM over the last few months, increasingRead More...

  • ACCESSWIRElast month

    Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want a free Stock Review on AXON sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com scans Actinium Pharmaceuticals Inc. (NYSE AMER: ATNM), Amarin Corp. PLC (NASDAQ: AMRN), Apricus Biosciences Inc. (NASDAQ: APRI), and Axovant Sciences Ltd (NASDAQ: AXON).

  • With A -24.18% Earnings Drop, Is Apricus Biosciences Inc’s (NASDAQ:APRI) A Concern?
    Simply Wall St.2 months ago

    With A -24.18% Earnings Drop, Is Apricus Biosciences Inc’s (NASDAQ:APRI) A Concern?

    After looking at Apricus Biosciences Inc’s (NASDAQ:APRI) latest earnings update (31 March 2018), I found it helpful to revisit the company’s performance in the past couple of years and compareRead More...

  • Associated Press2 months ago

    Apricus: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 14 cents. In the final minutes of trading on Thursday, the company's shares hit 26 cents. A year ago, they were trading at $1.16. ...

  • GlobeNewswire2 months ago

    Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results:

    Company Pursuing U.S. Vitaros Partnership and Strategic Alternatives SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company seeking to advance ...

  • GlobeNewswire2 months ago

    Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results

    Apricus Biosciences, Inc. (APRI), a biopharmaceutical company seeking to advance innovative medicines in urology and rheumatology, today reported financial results for the first quarter of 2018 and provided a corporate update on its near-term priorities. “Since our recent end-of-review meeting on the NDA for Vitaros with the FDA, we have been focused on pursuing U.S. Vitaros partnership discussions with interested parties.  Our objective is to enable continued development and potential approval of the Vitaros product and receive financial terms commensurate with this development stage asset in exchange for a sublicense or assignment of our U.S. development and/or commercialization rights.  In parallel, the Company is evaluating strategic alternatives, which may include a sale of the company, a business combination, a merger or reverse merger or a license, and in order to maximize shareholder value, the Company has engaged Canaccord Genuity LLC to assist in that process,” said Richard Pascoe, Chief Executive Officer.

  • Benzinga3 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Netflix, Inc. (NASDAQ: NFLX ) stock was trading higher ...

  • Reuters3 months ago

    Apricus mulls options; to sell U.S. rights to Vitaros

    Apricus Biosciences Inc said on Monday it was considering options for the company and looking to sell the U.S. rights to its erectile dysfunction cream Vitaros, after the Food and Drug Administration asked it to make a new formula for the product. Shares of the company fell 24 percent to 32 cents in premarket trading, valuing the company at $7.5 million.

  • Reuters3 months ago

    FDA asks for new formulation of Apricus' erectile dysfunction cream

    Drugmaker Apricus Biosciences Inc said on Monday the U.S. regulator directed it to develop a new formulation for its erectile dysfunction cream, Vitaros, which was rejected in February. The U.S. Food And ...

  • GlobeNewswire3 months ago

    Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA

    FDA Confirms Vitaros Regulatory Pathway  Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, ...

  • Market Exclusive4 months ago

    Edge Therapeutics And Apricus Biosciences Are Moving: Here’s Why

    Edge Therapeutics, Inc. (NASDAQ:EDGE) is grabbing all of the headlines in the biotechnology space heading into the close of this week on news that a trial rooted in one of its lead development assets has failed to hit the mark. The trial in question was looking at a drug called EG-1962. This is one of […] The post Edge Therapeutics And Apricus Biosciences Are Moving: Here’s Why appeared first on Market Exclusive.

  • GlobeNewswire4 months ago

    Apricus Biosciences Announces Pricing of $3.55 Million Public Offering

    SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has ...

  • GlobeNewswire4 months ago

    Apricus Biosciences Announces Proposed Public Offering

    SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has ...

  • GlobeNewswire4 months ago

    Apricus Biosciences Announces Scheduling of Vitaros(TM) End-of-Review Meeting with FDA

    Meeting Scheduled for April 12, 2018 SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, ...

  • ACCESSWIRE4 months ago

    Apricus Biosciences, Vitaros Update, The ED Market, Analysts Target Price, Pipeline

    NEW YORK, NY / ACCESSWIRE / March 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...

  • ACCESSWIRE4 months ago

    Blog Exposure - Cipher to Acquire Cardiome’s Canadian Business Portfolio for $25.5 Million in Cash

    Stock Monitor: Apricus Biosciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 22, 2018 / Active-Investors.com has just released a free research report on Cardiome Pharma Corp. (NASDAQ: CRME ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of APRI earnings conference call or presentation 1-Mar-18 9:30pm GMT

    Q4 2017 Apricus Biosciences Inc Earnings Call

  • Associated Press5 months ago

    Apricus reports 4Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 16 cents. In the final minutes of trading on Thursday, the company's shares hit 87 cents. A year ago, they were trading at $2.88. ...

  • GlobeNewswire5 months ago

    Apricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results

    Company Expects to Submit Vitaros End of Review Meeting Request This Month Vitaros End-of-Review Meeting Expected to Occur in April 2018 Company Expects Cash Runway Through 2018 Conference Call / Webcast ...